Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Tabeze, R. Borie, J. E. Kahn, E. Catherinot, B. Crestani, L. J. Couderc (Paris, Suresnes, France). Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome. Eur Respir J 2013; 42: Suppl. 57, 5121

Member's Comments

No comment yet.

Related content which might interest you: Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 Rituximab in severe, progressive interstitial lung disease Source: International Congress 2016 – Connective tissue disorders Year: 2016 The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy Source: International Congress 2014 – ILDs 4 Year: 2014 Tacrolimus for antisynthetase syndrome with interstitial lung disease? Source: Eur Respir J 2008; 32: 244-245 Year: 2008 Rituximab for the treatment of chronic hypersensitivity pneumonitis Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 Interstitial lung disease associated with polymyositis-dermatomyositis Source: Eur Respir J 2005; 26: Suppl. 49, 31s Year: 2005 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Metabolic syndrome in interstitial lung diseases Source: International Congress 2015 – IIPs: orphan Year: 2015 Progressive fibrosis is common in patients with Sjögren’s syndrome and Interstitial lung disease Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Antisynthetase syndrome (AS) in patients with diffuse interstitial lung disease (ILD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 Lymphangioma in patients with pulmonary lymphangioleiomyomatosis – Results of sirolimus treatment Source: International Congress 2016 – Orphan diseases I Year: 2016 The prognostic factor in patients with myositis-associated interstitial lung disease Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Rituximab in the management of idiopathic inflammatory myopathies complicated by interstitial lung disease Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 The role of detection of myositis specific and associated antibodies in Japanese patient with interstitial lung disease Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Variation in mortality from interstitial lung disease by diagnosis Source: International Congress 2015 – IIPs: orphan Year: 2015 Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT Source: International Congress 2016 – Clinical aspects of ILD Year: 2016